Physician
Hematology
Jay P. Klarnet, MD works in the field of Hematology. He went to medical school at University at Buffalo, School of Medicine and Biomedical Sciences. He over the years received 1 awards: "Meaningful Use Stage 1 Certification". Jay P. Klarnet is a published doctor as well. He has 23 publications published. The latest was: High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive Lymphoma or relapsed Hodgkin'...
- High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients With multiple myeloma.
- Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an Analysis of factors correlating with the tempo of e...
- Requirements for T Cell recognition and elimination of retrovirally-transformed Cells.
- High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian Cancer.
- High-dose busulfan, melphalan, thiotepa and peripheral blood stem cell infusion for the treatment of metastatic breast Cancer.
- Phase II study of high-dose busulfan, melphalan and thiotepa With autologous peripheral blood stem cell support in patients With malignant disease.
- Helper-independent CD8+ cytotoxic T lymphocytes express IL-1 receptors and require IL-1 for secretion of IL-2.
- Il-4 is an endogenous T cell growth factor during the Immune response to a syngeneic retrovirus-induced tumor.
- Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.
- Monoclonal antibody therapy of murine Lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
- Requirements for the generation of a Lyt-2+ T-Cell proliferative response to a syngeneic tumor in the absence of L3T4+ T-Cells.
- The role of B cells for in vivo T cell responses to a Friend virus-induced Leukemia.
- Effect of metronidazole on theophylline pharmacokinetics.
- Antigen-specific cultured T Cells can mediate tumor therapy and provide long-term immunologic memory in vivo.
- Eradication of disseminated murine Leukemia by treatment with high-dose interleukin 2.
- Therapy of disseminated tumors by adoptive transfer of specifically Immune T cells.
- Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated Leukemia, and provide specific immunologic memory.
- Antigen-driven long term-cultured T Cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T Cells.
- Effector mechanisms by which adoptively transferred T Cells promote tumor eradication.
- Specific adoptive immunotherapy.
- FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine Leukemia virus-encoded antigens.
Schools
University At Buffalo State University Of New York School Of Medicine
Millard Fillmore Hospital
University of Washington
Procedures Preformed
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
University of Washington
-
University at Buffalo, School of Medicine and Biomedical Sciences
Hospital
-
TMC Healthcare
Drug Facts
| NPI NUMBER |
|
1538258314 |
| NPPES Provider LastName |
|
KLARNET |
| NPPES Provider FirstName |
|
JAY |
| NPPES Provider ZIPCode |
|
992162258 |
| NPPES Provider State |
|
WA |
| Specialty Description |
|
Hematology/Oncology |
| Total Claim Count |
|
667.0 |
| Distinct Opioid Count |
|
3.0 |
| Opioid Claim Count |
|
59.0 |
| Percent Opioid Claims |
|
8.85 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1538258314 |
| Last Name Of The Provider |
KLARNET |
| First Name Of The Provider |
JAY |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.